Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

The British Journal of Dermatology
K A PappR J Israel

Abstract

Biologics are being used increasingly to treat moderate-to-severe psoriasis. Efficacy may differ in patients with previous exposure to biologics. To investigate the impact of previous biologic exposure on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. Two placebo- and ustekinumab-controlled phase III clinical trials. There was an initial 12-week induction phase where patients were treated with brodalumab [210 mg or 140 mg every 2 weeks (Q2W)], ustekinumab or placebo. Efficacy end points included ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment (score of 0 or 1) vs. placebo, PASI 100 vs. ustekinumab, Dermatology Life Quality Index and Psoriasis Symptom Inventory. Adverse events were monitored throughout. In total, 493 patients [334 (27%) brodalumab 210 mg Q2W and 159 (26%) ustekinumab] had received prior biologics; 150 (12%) and 62 (10%), respectively, reported previously failed treatment with a biologic. Brodalumab efficacy in patients with or without previous exposure to biologics was statistically equivalent: 40·9% and 39·5% of biologic-naive and -experienced patients achieved PASI 100 at week 12, compared wit...Continue Reading

References

Mar 20, 2009·The Journal of Investigative Dermatology·Erin G HarperAndrew Blauvelt
Aug 8, 2009·American Journal of Clinical Dermatology·Annamaria MazzottaSergio Chimenti
Jul 16, 2011·Dermatology : International Journal for Clinical and Investigative Dermatology·M AugustinM A Radtke
Nov 15, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·V Ruiz SalasA Alomar
Mar 30, 2012·The New England Journal of Medicine·Kim A PappScott Baumgartner
Oct 25, 2012·The British Journal of Dermatology·J Leman, A D Burden
Jan 19, 2013·Dermatology : International Journal for Clinical and Investigative Dermatology·Jenny M NorlinMarcus Schmitt-Egenolf
Aug 8, 2013·The Journal of Investigative Dermatology·Emily Edson-HerediaTomoko Maeda-Chubachi
Dec 21, 2013·Journal of the American Academy of Dermatology·Stefano PiasericoUNKNOWN Psocare Study Group
Jul 19, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Heather R Conti, Sarah L Gaffen
Aug 11, 2015·Dermatologic Therapy·Francisco Kerdel, Martin Zaiac
Oct 1, 2015·The New England Journal of Medicine·Mark LebwohlAjay Nirula
Mar 5, 2016·The Journal of Dermatological Treatment·Sphoorthi Jinna, Bruce Strober

❮ Previous
Next ❯

Citations

May 29, 2019·Immunotherapy·Ting-Shun Wang, Tsen-Fang Tsai
Dec 1, 2018·Expert Opinion on Biological Therapy·Annika Silfvast-KaiserAlan Menter
Sep 12, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·M C FargnoliUNKNOWN BRILLIANT Working Group
Jul 27, 2021·Expert Opinion on Drug Safety·Bénédicte CaronLaurent Peyrin-Biroulet

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.